导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.81% | 2902/4773 |
| 近一周 | -2.10% | 3386/5465 |
| 近一月 | -4.94% | 3538/5421 |
| 近一季 | -7.76% | 2955/5231 |
| 近半年 | -3.22% | 2430/4920 |
| 近一年 | 2.57% | 2248/4394 |
| 近两年 | 43.05% | 1769/2954 |
| 近三年 | 25.92% | 1262/2253 |
| 成立以来 | 129.44% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.43% 3199/4961 |
13.76% 1947/5312 |
- - |
- - |
| 2025 | 22.34% 1979/4813 |
- 2014/3635 |
1.04% 2486/4076 |
20.06% 2043/4524 |
0.85% 1716/4813 |
| 2024 | 13.30% 1156/3463 |
2.94% 658/2808 |
-0.87% 857/3014 |
15.54% 1688/3129 |
-3.91% 2404/3463 |
| 2023 | -10.18% 1273/2656 |
4.65% 893/2280 |
-4.57% 1203/2385 |
-3.41% 922/2515 |
-6.89% 1965/2655 |
| 2022 | -19.27% 827/2207 |
-13.09% 696/1919 |
7.30% 496/2016 |
-14.39% 1085/2113 |
1.12% 1379/2208 |
| 2021 | 0.13% 727/1822 |
-1.04% 422/1255 |
4.54% 876/1330 |
-4.95% 756/1466 |
1.84% 782/1822 |
| 2020 | 38.54% 354/1250 |
-9.00% 647/1028 |
13.01% 655/1067 |
15.32% 222/1164 |
16.82% 148/1184 |
| 2019 | 45.80% 143/1092 |
25.29% 471/754 |
3.38% 50/804 |
4.43% 201/850 |
7.79% 397/918 |
| 2018 | -17.17% 125/834 |
- - |
- - |
- - |
-11.22% 268/691 |
| 2017 | 33.91% 43/714 |
- - |
- - |
- - |
- - |
| 2016 | -6.11% 192/605 |
- - |
- - |
- - |
- - |
| 2015 | 0.08% 254/575 |
- - |
- - |
- - |
- - |
| 2014 | 58.47% 42/237 |
- - |
- - |
- - |
- - |
| 2013 | -9.98% 151/186 |
- - |
- - |
- - |
- - |
| 2012 | 11.92% 28/140 |
- - |
- - |
- - |
- - |
| 2011 | -19.29% 28/102 |
- - |
- - |
- - |
- - |
| 2010 | -17.04% 43/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华富中证A100指数A VS. 长安沪深300非周期A(740101) |